MARKET

MRSN

MRSN

Mersana Therapeutics Inc
NASDAQ
0.3639
+0.0016
+0.44%
After Hours: 0.3640 +0.0001 +0.03% 19:48 04/25 EDT
OPEN
0.3700
PREV CLOSE
0.3623
HIGH
0.3716
LOW
0.3500
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
3.630
52 WEEK LOW
0.2589
MARKET CAP
45.35M
P/E (TTM)
-0.6444
1D
5D
1M
3M
1Y
5Y
1D
MERSANA THERAPEUTICS ANNOUNCES UPCOMING EMI-LE ORAL AND POSTER PRESENTATIONS AT ASCO 2025 ANNUAL MEETING
Reuters · 2d ago
Weekly Report: what happened at MRSN last week (0414-0418)?
Weekly Report · 4d ago
Weekly Report: what happened at MRSN last week (0407-0411)?
Weekly Report · 04/14 09:03
Weekly Report: what happened at MRSN last week (0331-0404)?
Weekly Report · 04/07 09:03
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 04/04 15:05
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
Barchart · 04/01 07:01
Weekly Report: what happened at MRSN last week (0324-0328)?
Weekly Report · 03/31 09:04
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Simply Wall St · 03/27 10:32
More
About MRSN
More
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Recently
Symbol
Price
%Change

Webull offers Mersana Therapeutics Inc stock information, including NASDAQ: MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRSN stock methods without spending real money on the virtual paper trading platform.